<DOC>
	<DOC>NCT01324336</DOC>
	<brief_summary>The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).</brief_summary>
	<brief_title>Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Patients ages 417 years of age who are receiving maintenance chemotherapy treatment for ALL with 6MP will be included. Inability to have blood drawn for the screening lab tests Received methotrexate or folate supplement within the last 24 hours Pregnant or lactating females Inability to swallow a pill Hemoglobin less or equal to 8 gm/dl Presence of significant comorbid illness that makes child ineligible as deemed by the investigator Weight &lt; or = 16 kg</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>6-Mercaptopurine</keyword>
	<keyword>Pediatric</keyword>
</DOC>